NCT02224729View on ClinicalTrials.gov

Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 25, 2014

Primary Completion Date

April 21, 2016

Study Completion Date

November 17, 2018

Conditions

Stage I Multiple MyelomaStage II Multiple MyelomaStage III Multiple Myeloma

Interventions

DRUG

Bendamustine hydrochloride

Given IV

DRUG

Bortezomib

Given SC

DRUG

Dexamethasone

Given PO

Trial Locations (1)

19107

Thomas Jefferson University, Philadelphia

All Listed Sponsors

lead

Sidney Kimmel Cancer Center at Thomas Jefferson University

OTHER

NCT02224729 - Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma | Biotech Hunter | Biotech Hunter